Highly Potent Active Pharmaceutical Ingredients Conference


London, United Kingdom

We are delighted to announce our 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019.

The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.

The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimize risk and advanced manufacturing processes. In addition, the conference aims to guide attendees through novel regulatory updates for each stage of HPAPI development.

Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Benefits of Attending

  • LISTEN to Gedeon Richter on the risk assessment of highly potent APIs; from cross-contamination to transportation parameters
  • LEARN from AbbVie about containment improvement strategies
  • ASSESS the challenges of verifying containment performance of a HPAPI OSD facility in GSK's presentation
  • REVIEW adaptation of containment designs with AstraZeneca to cope with the high demands of HPAPIs
  • ATTEND the post-conference workshop which is a step-by-step road map assessing how to successfully roll out highly potent API projects

Who should attend

API specialists, Containment engineers, Senior Scientists, Head of Scale-up Processings, Occupational Health Officers, Industrial Hygiene Leads, Head of Bioconjugations, Sales Directors, Marketing Managers, Course Directors/ Lecturers

Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 15th May 2019

Workshop A: A Step-by-Step Road Map Assessing How To Successfully Roll Out Highly Potent API Projects  
Workshop Leader: Mr Justin Mason-Home, Director, HPAPI Project Services Limited
08.30 - 12.30

Workshop B: The Roadmap: Planning and Execution of a Successful Containment Performance Testing Campaign  
Workshop Leader: Mike Perry, Director, Pharmadagio Limited
13.30 - 16.30

Speakers

  • Mr Justin Mason-Home, Director, HPAPI Project Services Limited
  • David OConnell, Director Scientific Affairs, PCI Pharma Services
  • Dr Enrico Bettetini, R&D Technology and Pilot Manager, Teva Pharmaceuticals Ltd
  • Dr Ildiko Ziegler, Distinguished Validation Expert, Gedeon Richter Plc.
  • Dr Jack Brown, Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Dr Olindo Lazzaro, Director, Global EHS Technical Operations, AbbVie
  • Dr Thomas Adam, Head of Global Quality Assurance Chemical APIs, Bayer
  • Dr Thomas Nittoli, Director, Regeneron Inc
  • Dr Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer Pharma
  • Dr. Andrew Kyle, R&D Senior Chemist, SK Biotek
  • Fabio Zenobi, EHS Director, BSP Pharmaceuticals S.p.A.
  • Mike Perry, Director, Pharmadagio Limited
  • Mr Jeff Parry, Senior Formulation Scientist, Astrazeneca
  • Mr Martin Axon, Principal Occupational Hygienist, SafeBridge Europe Ltd
  • Mr Nigel Saunders, SME Containment, GSK
  • Mr Peter Marshall, Associate Engineer Director, AstraZeneca
  • Ms Ester Lovsin Barle, PhD, MScTox, ERT, Lonza

Venue

Copthorne Tara Hotel
Scarsdale Place, Kensington
London, United Kingdom